ZB014 / Zenas BioPharma - LARVOL DELTA

Early development programs (The Manila Times) - "ZB022, an oral, brain-penetrant, TYK2-JH2 inhibitor: IND enabling studies ongoing: Subject to the results of IND enabling studies, Zenas expects to initiate a Phase 1 clinical study in 2027...ZB014, a half-life extended, anti-CD19 and FcγRIIb monoclonal antibody (mAb): Zenas expects to advance the program into Phase 1 clinical development in 2027."

New P1 trial • Preclinical • Immunology • Inflammation

Early development programs (GlobeNewswire) - "IND enabling studies ongoing: Subject to the results of IND enabling studies, Zenas expects to initiate a Phase 1 clinical study in 2027....Developed using half-life extension technology for mAbs, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule. Zenas expects to advance the program into Phase 1 clinical development in 2027."

IND • Immunology • Inflammation

A new, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) is progressing toward clinical development (GlobeNewswire) - "Developed using half-life extension technology for monoclonal antibodies, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule."

New molecule • Immunology